<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Histone erasers in prostate cancer: Clearing the path for progression & therapy resistance

Simple item page
dc.contributor.departmentSchool of Medicine
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentGraduate School of Health Sciences
dc.contributor.kuauthorCevatemre, Buse
dc.contributor.kuauthorBulut, İpek
dc.contributor.kuauthorYüksel, Neslihan
dc.contributor.kuauthorKaryemez, Ezgi
dc.contributor.kuauthorAyhan, Ceyda Açılan
dc.contributor.kuauthorYıldız, Deniz
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF HEALTH SCIENCES
dc.date.accessioned2026-09-15T10:54:17Z
dc.date.issued2026
dc.description.abstractDrug resistance remains a significant hurdle in the effective treatment of prostate cancer (PC), leading to therapy failure and disease progression. The reversible nature of epigenetic modifications provides a potential for therapeutic intervention, presenting a promising approach to combat drug resistance. This two-part review first consolidates existing knowledge on epigenetic mechanisms—specifically histone deacetylases (HDACs) and histone demethylases (HDMs)—that drive PC progression and treatment resistance, emphasizing their therapeutic potential to enhance patient outcomes. The second section highlights epigenetic candidate drugs, focusing on those with preclinical evidence and a favorable profile for advancing into clinical trials as potential therapeutic options for PC.
dc.description.harvestedfromManual
dc.description.indexedbyPubMed
dc.description.indexedbyScopus
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipKoç Üniversitesi Translasyonel Tıp Araştırma Merkezi; Koç Üniversitesi
dc.description.versionPublished Version
dc.identifier.ScopusPercentile93
dc.identifier.ScopusQuartileQ1
dc.identifier.WoSPercentile85.9
dc.identifier.WoSQuartileQ1
dc.identifier.doi10.1016/j.critrevonc.2026.105563
dc.identifier.eissn1879-0461
dc.identifier.endpage105563
dc.identifier.grantnoN/A
dc.identifier.issn1040-8428
dc.identifier.pubmed42641833
dc.identifier.scopus2-s2.0-105049039804
dc.identifier.startpage105563
dc.identifier.urihttp://doi.org/10.1016/j.critrevonc.2026.105563
dc.identifier.urihttps://hdl.handle.net/20.500.14288/35327
dc.identifier.volume227
dc.languageeng
dc.publisherElsevier BV
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofCritical Reviews in Oncology/Hematology
dc.relation.openaccessN/A
dc.subjectOncology
dc.subjectHematology
dc.subjectCancer research
dc.titleHistone erasers in prostate cancer: Clearing the path for progression & therapy resistance
dc.typeReview
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication4c75e0a5-ca7f-4443-bd78-1b473d4f6743
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext